US2005096276A1PendingUtilityA1

Treatment of hibernating myocardium with a GLP-1 peptide

57
Priority: Oct 20, 2000Filed: Dec 8, 2004Published: May 5, 2005
Est. expiryOct 20, 2020(expired)· nominal 20-yr term from priority
Inventors:Thomas R. CoolidgeMario Ehlers
A61P 9/10A61P 9/04A61P 9/00A61K 38/26
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Hibernating myocardium is characterized by viable myocardium with impaired function due to localized reduced perfusion. Hibernating myocytes retain cellular integrity, but cannot sustain high-energy requirements of contraction. High plasma levels of catecholamines, such as norepinepherine, are believed to be predictive of mortality from hibernating myocardium. Likewise, high levels of catecholamines lead to cardiomyopathy in patients with diabetes. GLP-1 reduces plasma norepinepherine levels, and it thus is useful in a method of treating hibernating myocardium or diabetic cardiomyopathy.

Claims

exact text as granted — not AI-modified
1 - 40 . (canceled)  
     
     
         41 . A method for treating hibernating myocardium in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a GLP-1 or a peptide agonist analog thereof.  
     
     
         42 . The method according to  claim 41 , wherein said patient also suffers from congestive heart failure.  
     
     
         43 . The method according to  claim 41 , wherein said patient also suffers from ischemic cardiomyopathy.  
     
     
         44 . The method according to  claim 41 , wherein said patient also suffers from diabetic cardiomyopathy.  
     
     
         45 . The method according to  claim 41 , wherein said patient also suffers from pulmonary congestion.  
     
     
         46 . The method according to  claim 41 , wherein said therapeutically effective amount is effective to cause a reduction in plasma or heart norepinepherine levels.  
     
     
         47 . The method according to  claim 41 , wherein said GLP-1 or peptide agonist analog thereof is selected from the group consisting of GLP-1 (1-37), GLP-1 (1-36)NH 2 , GLP-1 (7-37), GLP-1 (7-36)NH 2 , and any combination thereof.  
     
     
         48 . The method according to  claim 41 , wherein said peptide agonist analog of GLP-1 contains a Ser or Thr amino acid substitution for the Ala at a position corresponding to position 8 of SEQ ID NO. 1.  
     
     
         49 . The method according to  claim 41 , wherein peptide agonist analog of GLP-1 contains a Asp amino acid substitution for the Glu at a position corresponding to position 9 of SEQ ID NO. 1.  
     
     
         50 . The method according to  claim 41 , wherein said GLP-1 or peptide agonist analog thereof is administered continuously.  
     
     
         51 . The method according to  claim 41 , wherein said GLP-1 or peptide agonist analog thereof is administered parenterally.  
     
     
         52 . The method according to  claim 50 , wherein said GLP-1 or peptide agonist analog thereof is administered at a dose of about 0.1 pmol/kg/min.  
     
     
         53 . The method according to  claim 50 , wherein said GLP-1 or peptide agonist analog thereof is administered subcutaneously at a dose of from about 0.5 pmol/kg/min to about 50 pmol/kg/min.  
     
     
         54 . The method according to  claim 50 , wherein said GLP-1 or peptide agonist analog thereof is administered intravenously at a dose of from about 0.1 pmol/kg/min to about 10 pmol/kg/min  
     
     
         55 . A method for treating hibernating myocardium in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of an exendin.  
     
     
         56 . The method according to  claim 55 , wherein said patient also suffers from congestive heart failure.  
     
     
         57 . The method according to  claim 55 , wherein said patient also suffers from ischemic cardiomyopathy.  
     
     
         58 . The method according to  claim 55 , wherein said patient also suffers from diabetic cardiomyopathy.  
     
     
         59 . The method according to  claim 55 , wherein said patient also suffers from pulmonary congestion.  
     
     
         60 . The method according to  claim 55 , wherein said therapeutically effective amount is effective to cause a reduction in plasma or heart norepinepherine levels.  
     
     
         61 . The method according to  claim 55 , wherein said exendin comprises exendin-4.  
     
     
         62 . The method according to  claim 55 , wherein said exendin comprises exendin-3.  
     
     
         63 . The method according to  claim 55 , wherein said exendin is administered continuously.  
     
     
         64 . The method according to  claim 55 , wherein said exendin is administered parenterally.  
     
     
         65 . The method according to  claim 63 , wherein said exendin is administered at a dose of about 0.1 pmol/kg/min.  
     
     
         66 . The method according to  claim 63 , wherein said exendin is administered subcutaneously at a dose of from about 0.5 pmol/kg/min to about 50 pmol/kg/min.  
     
     
         67 . The method according to  claim 63 , wherein said exendin is administered intravenously at a dose of from about 0.1 pmol/kg/min to about 10 pmol/kg/min  
     
     
         68 . A method for treating diabetic cardiomyopathy in a patient in need thereof comprising administering to said patient a therapeutically effective amount of an exendin.  
     
     
         69 . The method according to  claim 68 , wherein said therapeutically effective amount is effective to cause a reduction in plasma or heart norepinepherine levels.  
     
     
         70 . The method according to  claim 68 , wherein said exendin comprises exendin-4.  
     
     
         71 . The method according to  claim 68 , wherein said exendin comprises exendin-3.  
     
     
         72 . The method according to  claim 68 , wherein said exendin is administered continuously.  
     
     
         73 . The method according to  claim 68 , wherein exendin is administered parenterally.  
     
     
         74 . The method according to  claim 72 , wherein said exendin is administered at a dose of about 0.1 pmol/kg/min.  
     
     
         75 . The method according to  claim 72 , wherein said exendin is administered subcutaneously at a dose of from about 0.5 pmol/kg/min to about 50 pmol/kg/min.  
     
     
         76 . The method according to  claim 72 , wherein said exendin is administered intravenously at a dose of from about 0.1 pmol/kg/min to about 10 pmol/kg/min

Join the waitlist — get patent alerts

Track US2005096276A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.